TOP20 retail ophthalmic drugs released!

A few days ago, the CDE official website showed that Qilu Pharmaceutical’s sodium hyaluronate eye drops and bromfenac sodium eye drops were accepted as imitations of the same daily production of 4 categories
.
Since the beginning of this year, 7 products (15 product regulations) of ophthalmic drugs have been approved for marketing, and Hengrui Medicine won the first imitation of tafluprost eye drops; in addition, 17 products (56 product regulations) have been submitted for production under review No generic drugs such as brimonidine timolol eye drops and diquafosol sodium eye drops have been approved, involving companies such as Chengdu Shengdi Pharmaceutical and Shenyang Xingqi Eye Drops
.
According to data from Menet.
com, in recent years, the sales of terminal chemical ophthalmic drugs in physical pharmacies in cities in China have exceeded 3.
5 billion yuan, and it is expected to increase by 1.
89% year-on-year in 2021
.
In terms of TOP20 manufacturers, Shandong Bausch & Lomb Freda Pharmaceuticals, Mentholatum (China) Pharmaceuticals, and Hubei Yuanda Tiantian Ming Pharmaceuticals rank in the top three
.
13 of the TOP20 products have sales of more than 100 million yuan, and the former 1 billion products have fallen into the altar
.
Among the TOP20 brands, URSAPHARM's sodium hyaluronate eye drops have the fastest growth rate, exceeding 30%
.
The two major Qilu eye drops are produced in the same daily, Hengrui, Yangtze River, Xingqi.
.
.
The CDE official website shows that Qilu Pharmaceutical’s sodium hyaluronate eye drops and bromfenac sodium eye drops are all 4 types of imitations.
The production report on the same day is accepted, and after approval, it will be deemed as over-evaluated
.
Prior to this, Qilu Pharmaceuticals of these two products have been approved by product regulations, but they have not been reviewed
.
2021E Sales of sodium hyaluronate eye drops in physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mi Nei.
com, the terminal competition pattern of physical pharmacies in Chinese cities, sodium hyaluronate eye drops are commonly used drugs for the treatment of dry eye
.
According to data from Meinnet.
com, sodium hyaluronate eye drops is the TOP2 product for terminal chemical ophthalmic drugs in physical pharmacies in Chinese cities.
The sales growth rate has exceeded 20% in recent years.
With the largest market share, Santian Pharmaceutical and United Laboratories ranked second and third respectively
.
At present, the product has 10 companies including Nanjing Hengdao Pharmaceutical|Jiangsu Dahongying Hengshun Pharmaceutical, Beijing Huienlande Pharmaceutical, etc.

.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Qilu Pharmaceutical has 6 ophthalmic drug products, among which, Brimonidine Tartrate Eye Drops and Moxifloxacin Hydrochloride Eye Drops are reported as generic 4 types.
It was approved this year, and brimonidine tartrate eye drops were the first to be reviewed
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Since this year, 7 ophthalmic products (15 product regulations) have been approved for marketing.
Moxifloxacin hydrochloride eye drops are the most popular, Yangzijiang Pharmaceutical, Shenyang Xingqi Eye Medicine 7 companies including Zhuhai Essex Biopharmaceuticals were approved; Hengrui Pharmaceuticals won the first imitation of tafluprost eye drops.
Prior to this, the only manufacturer of this product was Shantian Pharmaceuticals, which is expected to be available in physical pharmacies in Chinese cities in 2021.
The sales of terminal tafluprost eye drops increased by nearly 50% year-on-year
.
In addition, there are 17 products (56 product regulations) that are under review.
Among them, moxifloxacin hydrochloride eye drops have the largest number of companies, with 9 companies, followed by sodium hyaluronate eye drops, with 7 companies; Nidine Timolol Eye Drops, Diquafosol Sodium Eye Drops, Bimesol Timolol Eye Drops and other products have not been approved for generic drugs, involving Qilu Pharmaceutical, Yangzijiang Pharmaceutical, Chengdu Shengdi Pharmaceutical , Shenyang Xingqi Eye Medicine, Zhaoke (Guangzhou) Ophthalmology and many other enterprises
.
The ophthalmic medicine retail market makes waves again! Xingqi surged over 40% in recent years, the sales of terminal chemical drugs in physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mi Nei.
com China’s urban physical pharmacies terminal competition pattern Mi Nei.
com data show that in recent years, Chinese urban physical pharmacies terminal chemical drugs The market sales of ophthalmic drugs exceeded 3.
5 billion yuan, and it is expected to increase by 1.
89% year-on-year in 2021
.
From the perspective of sub-categories, the total market share of other ophthalmic drugs, anti-infectives, anti-congestants and anti-allergic drugs exceeds 80%.
Among them, the sales scale of other ophthalmic drugs and anti-infectives exceeds 1 billion yuan.

.
In recent years, the market share of TOP3 manufacturers of chemical ophthalmic drugs in Chinese urban physical pharmacies.
Source: Mynet.
com.
Chinese urban physical pharmacy terminal competition pattern.
From the perspective of the TOP20 manufacturers, Shandong Bausch & Lomb Furuida Pharmaceuticals, Mentholatum (China) Pharmaceuticals, Hubei Yuanda Tiantianming Pharmaceutical ranks in the top three; Shenyang Xingqi Eye Drugs has the fastest growth rate, exceeding 40%, ranking close to the top ten, jumping from the 16th place in 2020 to the 11th place in 2021
.
TOP20 is out! The sales of 13 products exceeded 100 million yuan, and the previous 1 billion varieties fell into the altar.
2021E China's urban entity pharmacies terminal chemical drugs ophthalmic drug products TOP20 sales (unit: 100 million yuan) Source: Mynet.
com.
China urban entity pharmacies terminal competition pattern Note: Sales Less than 100 million yuan * means that of the TOP20 products, 13 products have sales of more than 100 million yuan.
Among them, the top three naphthalene vitamin eye drops, sodium hyaluronate eye drops, and compound aspartame eye drops are all More than 300 million yuan
.
In addition, ranibizumab injection and escin and digitalis eye drops are exclusive products
.
In terms of growth rate, sodium hyaluronate eye drops were the fastest, exceeding 20%, and ranked second; the growth rates of levofloxacin eye drops, levofloxacin hydrochloride eye drops, and tobramycin eye drops all exceeded 10%
.
2021E China city entity pharmacy terminal chemical medicine ophthalmic drug brand TOP20 sales situation (unit: 100 million yuan) Source: Mi Nei.
com China city entity pharmacy terminal competition pattern Note: sales of less than 100 million yuan use * to indicate that there are 7 sales in the TOP20 brands The amount exceeds 100 million yuan
.
In terms of growth rate, URSAPHARM's sodium hyaluronate eye drops have the fastest growth rate, exceeding 30%; Santian Pharmaceutical's levofloxacin eye drops and Jiangxi Zhenshiming Pharmaceutical's compound urine retinol eye drops have both exceeded 10%
.
In terms of the number of brands, Shandong Bausch & Lomb Freda Pharmaceuticals has the most, with 3; Mentholatum (China) Pharmaceuticals, Hubei Yuanda Tiantian Pharmaceuticals, Jiangxi Shining Pharmaceuticals, Santen Pharmaceuticals, and Novartis each have 2 on the list.

.
Sales of Naminwei Eye Drops in Chinese Urban Entity Pharmacies in 2021E (Unit: 100 million yuan) Source: Mi Nei.
com, China’s urban physical pharmacies terminal competition pattern.
According to data from Mi Nei.
It has steadily climbed.
After becoming a TOP1 product in 2019, it will exceed 400 million yuan in 2020 and is expected to reach a new high in 2021
.
At present, there are more than 20 companies producing Naminwei eye drops.
Among them, Shandong Bausch & Lomb Freda Pharmaceuticals has the largest market share, Jiangxi Shining Pharmaceuticals and Shenyang Xingqi Eyedrops rank second and third respectively
.
It is worth mentioning that Benda/Lysine eye drops used to be the TOP1 product for terminal chemical ophthalmic drugs in physical pharmacies in Chinese cities.
Sales in 2016 were nearly 1 billion yuan.
In 2017, it was negatively affected by events such as Sharp , Sales have been declining all the way, and "halved" in 2018.
It is expected to drop by 11.
57% year-on-year in 2021, and the ranking will fall to fifth place
.
Source: CDE official website, Meinenet database, etc.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database covers 297 prefecture and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Enlarged version of the city's physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
If there are any omissions, please correct me!